Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression.
Telomerase activation is a common feature of most advanced human cancers and is postulated to restore genomic stability to a level permissive for cell viability and tumor progression. Here, we used genetically defined transformed mouse embryonic fibroblast (MEF) cultures derived from late generation mTerc(-/-) Ink4a/Arf(-/-) mice to explore more directly how telomere-based crisis relates to the evolution of cancer cell genomes and to tumor biology. An exhaustive serial analysis of cytogenetic profiles over extensive passage in culture revealed that the emergence of chromosomal fusions (including dicentrics) coincided with onset of deletions and complex nonreciprocal translocations (NRTs), whereas mTerc-transduced cultures maintained intact chromosomes and stable genomes. Despite a high degree of telomere dysfunction and genomic instability, transformed late passage mTerc(-/-) Ink4a/Arf(-/-) cultures retained the capacity to form subcutaneous tumors in immunocompromised mice. However, even moderate levels of telomere dysfunction completely abrogated the capacity of these cells to form lung metastases after tail-vein injection, whereas mTerc reconstitution alone conferred robust metastatic activity in these cells. Finally, serial subcutaneous tumor formation using late passage transformed mTerc(-/-) Ink4a/Arf(-/-) cultures revealed clear evidence of telomerase-independent alternative lengthening of telomeres (ALT). Significantly, despite a marked increase in telomere reserve, cells derived from the ALT+ subcutaneous tumors were unable to generate lung metastases, indicating in vivo functional differences in these principal mechanisms of telomere maintenance. Together, these results are consistent with the model that although telomere dysfunction provokes chromosomal aberrations that initiate carcinogenesis, telomerase-mediated telomere maintenance enables such initiated cells to efficiently achieve a fully malignant endpoint, including metastasis.
Chang
Sandy
S
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Khoo
Christine M
CM
Naylor
Maria L
ML
Maser
Richard S
RS
DePinho
Ronald A
RA
D000818:Animals; D002461:Cell Line, Transformed / Q000201:enzymology / Q000473:pathology / Q000637:transplantation; D002869:Chromosome Aberrations; D020223:Chromosome Painting; D002875:Chromosomes / Q000648:ultrastructure; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000172:deficiency; D004622:Embryo, Mammalian / Q000166:cytology; D005347:Fibroblasts / Q000201:enzymology / Q000473:pathology / Q000637:transplantation; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000556:secondary; D051379:Mice; D018345:Mice, Knockout; D016513:Mice, SCID; D009363:Neoplasm Proteins / Q000502:physiology*; D009368:Neoplasm Transplantation; D012313:RNA / Q000235:genetics; D019098:Telomerase / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D016615:Telomere / Q000502:physiology*
D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; C422952:telomerase RNA; D012313:RNA; D019098:Telomerase